Evidence map›Paper›PMID 40595126›Full record

ArticleScientific reports2025

SREBP-2 promotes cancer progression through the mevalonate-Akt pathway in non-small cell lung cancer.

Wenjie You, Lili Su, Shuping Weng, Jing Li, Xingguang Wang, Bin Liang, Daowei Li, Lijun Li, Haiquan Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Wenjie You *Departments of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Dong-An Road 270#, Shanghai, 200032, China.
Lili Su *Department of Respiratory and Critical Care Medicine, Shandong Provincial Hospital affiliated to Shandong First Medical University, Jinan, 250021, Shandong, China.
Shuping Weng *Institute of Immunotherapy, Fujian Medical University, Xue-Yuan Road 1#, University Town, Fuzhou, 350122, Fujian, China.
Jing LiDepartment of Respiratory and Critical Care Medicine, Shandong Public Health Clinical Center, Jinan, 250013, Shandong, China.
Xingguang WangDepartment of Respiratory and Critical Care Medicine, Shandong Provincial Hospital affiliated to Shandong First Medical University, Jinan, 250021, Shandong, China.
Bin LiangDepartment of Respiratory and Critical Care Medicine, Shandong Provincial Hospital affiliated to Shandong First Medical University, Jinan, 250021, Shandong, China.
Daowei LiDepartment of Respiratory and Critical Care Medicine, Shandong Provincial Hospital affiliated to Shandong First Medical University, Jinan, 250021, Shandong, China.
Lijun LiInstitute of Immunotherapy, Fujian Medical University, Xue-Yuan Road 1#, University Town, Fuzhou, 350122, Fujian, China. muzilijun@fjmu.edu.cn.ORCID http://orcid.org/0000-0003-0443-0596
Haiquan ChenDepartments of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Dong-An Road 270#, Shanghai, 200032, China. hqchen1@yahoo.com.ORCID http://orcid.org/0000-0001-7846-257X

Funding

China Postdoctoral Science Foundation 2023M740684Jinan Science and Technology Plan Project (China) 202019201National Natural Science Foundation of China 81902325National Natural Science Foundation of China 81930073National Natural Science Foundation of China 82104203Shandong Provincial Natural Science Foundation (China) ZR2023QH021Shanghai Technology Innovation Action Project (China) 20JC1417200
6 · The paper itself

Abstract

Sterol regulatory element-binding protein-2 (SREBP-2) is a transcriptional factor, which mainly regulates cholesterogenesis-associated genes. The metabolism of cholesterol was found to be abnormal in non-small cell lung cancer (NSCLC). However, the clinical relevance of SREBP-2 in NSCLC has yet to be elucidated. Herein, the prognostic significance of SREBP-2 in NSCLC patients, and the functional roles of SREBP-2 in NSCLC proliferation, migration and invasion was examined. Then, therapeutic potential of targeting SREBP-2 in NSCLC was evaluated using mouse xenograft tumor models. We found that SREBP-2 was significantly increased in NSCLC, as compared with pericarcinous lung tissues. High expression of SREBP-2 was associated with poor clinical characteristics, and predicted a shorter overall survival (OS) in NSCLC patients. Cox multivariate regression revealed that high SREBP-2 expression served as an independent predictor for poor OS. Biofunctional analysis showed that gene silencing of SREBP-2 abrogated the proliferation, migration and invasion of NSCLC cells, while enforced SREBP-2 promoted NSCLC cell proliferation, migration and invasion. Mechanistically, SREBP-2 was found to promote cell proliferation, migration and invasion via the mevalonate-Akt pathway in NSCLC cells. Further in vivo treatment experiments showed that SREBP inhibitor decreased NSCLC tumor growth in mouse xenograft models in vivo. In combination, this study dissected the clinical significance and oncogenic role of SREBP-2 in NSCLC progression, providing evidence that have both prognostic and therapeutic implications.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsMevalonic AcidProto-Oncogene Proteins c-aktSterol Regulatory Element Binding Protein 2AnimalsCell Line, TumorCell MovementCell ProliferationDisease ProgressionFemaleGene Expression Regulation, NeoplasticHumansMaleMiceMice, NudeMevalonic AcidProto-Oncogene Proteins c-aktSREBF2 protein, humanSterol Regulatory Element Binding Protein 2Akt signaling pathwayCholesterol metabolismNon-small cell lung cancerPrognostic indicatorSterol regulatory element-binding protein-2

Identifiers

PMID40595126
PMCPMC12219647

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.